US › Healthcare

Evaxion Biotech AS (EVAX)

US · Healthcare · Biotechnology

$2.95+5.73%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-3.6M
Profit YoY
-129.7%
EPS
$-0.01
EPS estimate
$-0.01

EPS came in at -0.01 against a street estimate of -0.01 — a beat of 0.0%.

Key statistics

Market cap
$23.5M
Forward P/E
3.6
P/B
2.14
Book value
$1.58
EPS (TTM)
$-1.00
52-week high
$12.15
52-week low
$2.52
50-day MA
$3.38
200-day MA
$4.34
Beta
0.26

Analyst view

Analysts rate Evaxion Biotech AS a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $11.25.

Shareholding

Insiders
17.47%
Institutions
9.71%

Largest institutional holders

FundStake
Ikarian Capital, LLC0.90%
Rathbone Brothers PLC0.55%
Renaissance Technologies Corp0.47%
Annis Gardner Whiting Capital Advisors LLC0.36%
XTX Topco Ltd0.26%
Rhumbline Advisers0.26%
Stonepine Capital Management Llc0.24%
BOOTHBAY FUND MANAGEMENT, LLC0.22%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Evaxion Biotech AS — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.